
Perioperative Antiplatelet Therapy In Patients With Drug-Eluting Stent Undergoing Noncardiac SURgEry

ASSURE-DES Randomized Trial

Jung-Min Ahn, MD.

Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Preoperative, Intraoperative, and Postoperative Factors Associated with Perioperative Cardiac Complications in Patients Undergoing Major Noncardiac Surgery



N Engl J Med 2015;373:2258-69

28th TCTAP

Non-Cardiac Surgery and Cardiac Events

Catheterization and Cardiovascular Interventions 65:516-519 (2005)

Late Thrombosis of Sirolimus-Eluting Stents Following Noncardiac Surgery


Mithal Nasser, MD, Michael Kapeliovich, MD, and Walter Markiewicz,* MD, FACC


We describe two patients with in-stent thrombosis occurring 4 and 21 months after implantation of sirolimus-eluting stents. Both cases occurred following noncardiac surgery. In both cases, aspirin had been stopped prior to surgery. Both patient sustained a severe myocardial infarction; one died. The occurrence of late thrombosis of sirolimus-eluting stents is of concern. © 2005 Wiley-Liss, Inc.


Key words: acute thrombosis; stent; drug-eluting stent; percutaneous coronary intervention; complication; myocardial infarction

INTRODUCTION


Stent thrombosis is a feared complication of percutaneous coronary interventions [1,2]. Overall incidence following bare stent implantation is < 1-2% when underwent an excision biopsy of an enlarged right supraclavicular node under general anesthesia. The procedure lasted ~ 40 min and was uneventful. Aspirin had been stopped 10 days earlier. Two hours following the procedure, the patient complained of












8th TCTA

How Many Patients with DES Need Non-Cardiac Surgery ?



Circ Cardiovasc Interv. 2012;5:237-246

2016 ACC/AHA Focused Update

2014 ESC/ESA Guidelines

COR	LOE	Recommendations
I		Elective noncardiac surgery should be delayed 30 days after BMS implantation and optimally 6 months after DES implantation (101-103,143-146).
I	C-EO	In patients treated with DAPT after coronary stent implantation who must undergo surgical procedures that mandate the discontinuation of P2Y ₁₂ inhibitor therapy, it is recommended that aspirin be continued if possible and the P2Y ₁₂ platelet receptor inhibitor be restarted as soon as possible after surgery.
Па	C-EO	When noncardiac surgery is required in patients currently taking a $P2Y_{12}$ inhibitor, a consensus decision among treating clinicians as to the relative risks of surgery and discontinuation or continuation of antiplatelet therapy can be useful.
Пь	C-EO	Elective noncardiac surgery after DES implantation in patients for whom P2Y ₁₂ inhibitor therapy will need to be discontinued may be considered after 3 months if the risk of further delay of surgery is greater than the expected risks of stent thrombosis.
III: Harm	B-NR	Elective noncardiac surgery should not be performed within 30 days after BMS implantation or within 3 months after DES implantation in patients in whom DAPT will need to be discontinued perioperatively (101-103,143-146).

Independently of the timeframe between DES implantation and surgery, single anti-platelet therapy (preferably with aspirin) should be continued.




2022 ESC Guidelines

Recommendations	Class ^a	Level ^b
It is recommended to delay elective NCS until 6 months after elective PCI and 12 months after an ACS. ^{264,271}	I.	A
After elective PCI, it is recommended to delay time-sensitive NCS until a minimum of 1 month of DAPT treatment has been given. ^{266,271,288,289}	1	в
In patients with a recent PCI scheduled for NCS, it is recommended that management of antiplatelet therapy is discussed between the surgeon, anaesthesiologist, and cardiologist.		с
In high-risk patients with a recent PCI (e.g. STEMI patients or high-risk NSTE-ACS patients), a DAPT duration of at least 3 months should be considered before time-sensitive NCS.	lla	с
Continuation of medication		
In patients with a previous PCI, it is recommended to continue aspirin peri-operatively if the bleeding risk allows. ²⁴⁴	I.	В

Recommended time interval for drug interruption before NCS

I.	с
ШΒ	В
I	с
	I


Subgroup: POISE-2



Ann Intern Med. 2018;168:237-244.


CVRF

POISE-2: Aspirin in NCS




N Engl J Med 2014;370:1494-503.

ATACAS: Aspirin in CABG




Among patients undergoing coronary artery surgery, the administration of preoperative aspirin resulted in *neither a lower risk of death or thrombotic complications nor a higher risk of bleeding than that with placebo*.

Severance Cardiovascular Hospital Registry



Am J Cardiol. 2019 May 1;123(9):1414-1421

PARIS Registry



Myocardial Infarct	ON Hazard ratio (95% CI)	p value	Observed	Expected
On-DAPT	1.00 (Ref)		116	116.0
Discontinuation	0.92 (0.53-1.58)	0.748	18	19.7
Interruption	1.20 (0.55-2.63)	0.647	7	5.8
Disruption	2.95 (1.99-4.38)	<0.0001	39	13.2
0–7 days	18.25 (8.34-39.95)	<0.0001	7	0.4
8-30 days	4.69 (1.71-12.83)	0.003	4	0.9
>30 days	2.22 (1.42-3.46)	<0.0001	28	12.6
0.250-5 1 2 4 Stent Thrombosis	8 16 32 64 Hazard ratio (95% Cl) p value	Observed	Expected
Dn-DAPT	1.00 (Ref)		57	57.0
Discontinuation	0.39 (0.11-1.35)	0.137	3	7.7
nterruption	- 0.64 (0.09-4.82)	0.664	1	1.6
Disruption —	- 2.58 (1.22-5.46)	0.013	10	3.9
0-7 days	— 1 5·94 (5·57–45·58)	<0.000	1 4	0.3
8-30 days	2.68 (0.36-19.68)	0.334	1	0.4
>30 days	- 1.35 (0.50–3.64)	0.551	5	3.7
0.25 0.5 1 2	4 8 16 32 64			
Cardiac Death	Hazard ratio (95% Cl) p value	Observed	Expected
Dn-DAPT	1.00 (Ref)		100	100.0
Discontinuation	0.64 (0.36-1.16)	0.141	15	23.3
nterruption —	1.06 (0.48-2.34)	0.885	7	6.6
Disruption -	- 1.68 (1.05–2.67)	0.029	26	15.5

Discontinuation		0.64 (0.36-1.16)	0.141	15	23.3
Interruption	_ -	1.06 (0.48-2.34)	0.885	7	6.6
Disruption		1.68 (1.05-2.67)	0.029	26	15.5
0-7 days		<u> </u>	0.016	2	0.3
8-30 days		3.44 (1.08-10.98)	0.037	3	0.9
>30 days	+ - -	1.44 (0.87-2.38)	0.161	21	14.6
0.	250.51248	16 32			

28th TCTAP

Lancet. 2013 Nov 23;382(9906):1714-22

Antiplatelet Cessation vs. Maintenance: Summary of Studies


2007년-2019년

5 Observational Study and 4880 Patients


► Maintenance (N=2144) ^{Cessation} (N=2736)

		C	top	Date	<u>.</u>	50
연구자/발표년도	허혈성 사건	중단군	유지문	출혈성 사건	중단군	유지군
Schoos M et al. 2017	MI	2/254	3/340	N/A	N/A	N/A
Tokushige A et al. 2012	Death, MI or Stroke	26/1088	5/416	GUSTO moderate or severe Bleeding	27/1044	7/403
Graham M et al. 2017	Death or MI	27/236	14/234	POISE-2 Major or Life-threatening Bleeding	10/236	13/234
Rossini R et al. 2015	Cardiac death, MI, or Stroke	30/371	1/295	BARC 3 Bleeding	65/371	34/295
Hong SJ et al. 2019	Death, MI, or Stent thrombosis	6/787	15/859	ISTH Major Bleeding	1/787	0/859

Ischemic Events



Bleeding Events




^р тстар

A US National, Retrospective Cohort Study (N=41 989)

	Overall	MACE	No MACE	P Value	
Antiplatelet medication prior to surgery					
Dual	328 (57.8)	170 (59.9)	158 (55.6)		
Single	206 (36.3)	100 (35.2)	106 (37.3)	.43	
None	34 (6.0)	14 (4.9)	20 (7.0)		
Antiplatelet management at surgery					
Dual therapy					
All therapy continued	216 (65.9)	114 (67.1)	102 (64.6)		
Clopidogrel held	36 (11.0)	16 (9.4)	20 (12.7)	0.2	
Aspirin held	14 (4.3)	7 (4.1)	7 (4.4)	.82	
All therapy held	62 (18.9)	33 (19.4)	29 (18.4)		
Aspirin only					
Continued	143 (82.7)	70 (87.5)	73 (78.5)	12	
Held	30 (17.3)	10 (12.5)	20 (21.5)	.12	
Clopidogrel only					
Continued	22 (66.7)	12 (60.0)	10 (77.0)	.31	
Held	11 (33.3)	8 (40.0)	3 (23.1)		
Antiplatelet cessation >5 d, all held					
Yes	137 (24.1)	65 (22.9)	72 (25.4)	40	
No	431 (75.9)	219 (77.1)	212 (74.7)	.49	

JAMA. 2013;310(14):1462-1472

Perioperative Antiplatelet Therapy In Patients With Drug-Eluting Stent Undergoing Noncardiac SURgEry



Objectives

This trial compared the clinical efficacy and safety of antiplatelet therapy in patients undergoing non-cardiac surgery for more than 12 months after PCI with DES.

This trial compared outcome of discontinued antiplatelet treatment group and aspirin-alone treatment group.

Primary endpoint

The Composite of Death, Stent Thrombosis, MI, Stroke (5 days before and 30 days after Non-cardiac Surgery)

Inclusion Criteria

- 1) Men and women aged 19 years or more
- 2) Patients who implanted \geq 1 coronary drug-eluting stents
- 3) Patients scheduled for surgery at more than 12 months after PCI
- 4) Patients scheduled for elective non-cardiac surgery under general anesthesia

Exclusion Criteria


- 1) Patient who currently have ACS or MI within 1 month
- 2) Patient with dyspnea (NYHA III~IV) due to severe LV dysfunction (EF ≤30%) or severe VHD
- 3) Patient who have Intolerance for aspirin
- 4) Patient who need for anticoagulation therapy
- 5) Emergent operation
- 6) Cardiac surgery
- 7) High bleeding risk op. (Intra-cranial, Intra-spinal, Retinal surgery)
- 8) Pregnant and/or lactating women



Sample Size

Based on the results of the study in the POISE-2 trial, the primary endpoints of each treatment group were estimated. We will randomize 900 patients over 12 months after coronary stenting by 1:1 fashion, a) aspirin-alone treatment, b) discontinuation of antiplatelet agents. The assumed primary endpoint event rate was assumed 6.0% in aspirinonly therapy group and 11.5% in antiplatelet therapy discontinuation group. We estimated that enrollment of 900 patients would provide the study with 80% power to establish superiority of aspirin-only therapy in primary end point at 30 days, at a two-side type I error rate of 0.05.

POISE-2 (Ann Intern Med. 2018;168:237-244)




TRIAL PROCEDURES AND FOLLOW-UP

- Patients are randomized to Aspirin-alone or Non-Antiplatelet group.
- Aspirin-alone group takes only aspirin from 5 days before surgery.
- Patients on a single P2Y12 inhibitor change to aspirin from 5d before operation.
- Patients on DAPT change to single aspirin from 5 days before operation.
- DAPT is resumed postoperatively as soon as possible (if possible, POD #2)
- Non-antiplatelet group discontinue all antiplatelet agent from 5 days before op. Antiplatelet agent is resumed as soon as possible after op.
- All patients are followed up by OPD visits or telephone at 30 day after surgery.



Perioperative Antiplatelet Therapy In Patients With Drug-Eluting Stent Undergoing Noncardiac SURgEry



Current Status



28th TCTAP

Summary

- The ASSURE-DES trial is a prospective, multicenter, and randomized study to compare the safety and efficacy of aspirin cessation or not in perioperative period of non-cardiac surgery in patient who have undergone PCI with DES for more than 12 months.
- It may help to determine optimal antiplatelet therapy in patient who underwent PCI with

DES before non-cardiac surgery.

